DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

Information source: Par Pharmaceutical, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Ondansetron (Drug); Zofran (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Par Pharmaceutical, Inc.

Official(s) and/or principal investigator(s):
Christian Aumais, Principal Investigator, Affiliation: Algotithme Pharma Inc


To compare the single-dose bioavailability of Ondansetron 8 mg oDT and Zofran 8 mg ODT

Clinical Details

Official title: Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 8 mg ODT With That of GlaxoSmithKine's Zofran 8 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Rate and Extend of Absorption

Detailed description: To Compare the single-dose bioavailability of Kali's Ondansetron 8 mg ODT with that of GlaxoSmithKine's Zofran 8 mg ODT under fasting conditions


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Subjects meeting all of the following criteria may be included in the study.

- Availability of subject for the entire study period and willingness to adhere to

protocol requirements as evidenced by the informed consent form duly signed by the subject.

- Males and Females aged from 18 to 50 years ol with a body mass index (BMI)within

19-30; demographic data (sex, age, ethnic group, body weight, height and smoking habits) will be recorded and reported in the final report.

- Clinical laboratory values within the laboratory's stated normal range; if not within

this range, they must be without any clinical significance and must be recorded as such in the CRF (laboratory tests are presented in section 7. 1.3.

- Healthy according to the laboratory results and physical examination.

- Normal cardiovascular function according to ECG.

- Non or ex-smokers.

Exclusion Criteria:

- Significant history of hypersensitivity to ondansetron or any related products as

well as severe hypersensitivity reactions (like angioedema) to any drugs.

- Presence or history of significant gastrointestinal, liver or kidney disease, or any

conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.

- Presence or history of significant cardiovascular, pulmonary, hematologic,

neurologic, psychiatric, endocrine, immunologic or dermatologic disease.

- Females who are pregnant, lactating or are likely to become pregnant during the study


- Females of childbearing potential who refuse to use an acceptable contraceptive

regimen throughout the body.

- Positive pregnancy test before and during the study.

- Maintenance therapy with any drug, or significant history or drug dependancy, alcohol

abuse (>3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or serious psychological disease.

- Any clinically significant illness in the previous 28 days before day 1 of this


- Use of enzyme-modifying drugs in the previous 28 days before 1 day of this study (all

barbiturates, corticosteroids, phenylhydantoins, etc.).

- Participation in another clinical trial in the previous 28 days before day 1 of this


- Donation of 500 mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies,

etc.) in the previous 56 days before day 1 of this study.

- Positive urine screening of drugs of abuse (drug names are presented in section

7. 1.4).

- Positive results to HIV, HBsAg or anti-HCV tests.

- History of fainting upon blood sampling.

Locations and Contacts

Additional Information

Starting date: August 2002
Last updated: April 10, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017